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Surveillance of nosocomial infections in 
Europe: which methodologies? 
Prevalence studies in Europe 
D. Pittet. Infection Control P r o p m ,  The University o f  Geneva 
Hospitals, Switzerland 
Patients admitted to the hospital are at risk of developing nosocomial 
infections (NIs). Surveillance of NIs has been widely accepted 
throughout the world as a primary step towards prevention. The gold 
standard is prospective, on-site, continuous, hospital-wide surveil- 
lance; however, incidence surveys require exhaustive resources. Only 
a few hospitals perform ongoing surveillance for NIs, as do hospitals 
in the USA linked with the NNIS system, CDC. Prevalence studies 
are preferred, primarily due to limited resources, and have been 
conducted during the last 25 years in most European countries. 
Repetitive prevalence surveys are commonly used to assess the 
importance of NIs, and priorities for and impact of infection control. 
Prevalence rates of NIs in European hospitals ranged between 3.5 
and 14.8 per 100 admissions. Methodologies varied between studies. 
To compare the results of a prevalence study on NIs with those of 
other studies requires a knowledge and critical understanding of the 
methods applied. Differences in infection rates might be related to 
differences in surveillance methods and/or study populations; 
furthermore, time of the study and time trends must be considered. 
Thus, important parameters for the interpretation of the study 
findings include the selection of patients and adjustment for case-mix 
and time trends, the methods for identification of NIs, and the 
qualification, training and validation of the observer(s). 
Based on presently available information from national prevalence 
studies in Europe, comparison of infection rates between countries 
should be avoided; consecutive prevalence surveys in the same 
country seem, however, acceptable to assess trends and priorities for 
infection control. 
wl Resistance to antibiotics in European lCUs 
H. Hanberger. Department of Infectious Diseases, University Hospital, 
Linkopping, Sweden 
A high prevalence of decreased antibiotic susceptibility among Gram- 
negative bacilli and Staphylococcus aureus has been reported from ICU 
patients in several European countries. The National Nosocomial 
Infections Surveillance System ofthe Centers for Disease Control and 
Prevention monitors secular trends of antibiotic resistance rates of 
nosocomial pathogens in US hospitals. However, no corresponding 
international surveillance system is operational in Europe. We 
conducted a cross-country comparison of the incidence of antibiotic 
resistance among Gram-negative bacilli from patients in ICUs in 118 
hospitals in Belgium, France, Portugal, Spain and Sweden. Con- 
secutive specimens collected on clinical indications from ICU 
patients were cultured and tested. Minimal inhibitory concentrations 
were determined using Etest. Nine thousand one hundred and sixty- 
six Gram-negative strains were initially isolated from 7308 patients 
between June 1994 and June 1995. MIC breakpoints recommended 
by the National Committee for Clinical Laboratory Standards were 
used. The most frequently isolated organisms were Entero- 
bacteriaceae (59%). followed by Pseudomonas aemginosa (24%). The 
main sources were the respiratory tract (42%), urine (26%), blood 
(14%), abdomen (11%) and skin and soft tissues (7%). Decreased 
antibiotic susceptibility across all species and drugs was highest in 
Portuguese ICUs, followed by French, Spanish, Belgian and Swedish 
ICUs. The highest incidence of resistance was seen in all countries 
among I? aerufinosa (up to 37% resistant to ciprofloxacin in Portu- 
guese lCUs and 46% resistant to gentamicin in French ICUs), 
Enterobacter spp., Acinetobacter spp. and Stenotrophomonas rnaltophilia, 
and in Portugal and France among Klebsiella spp. 
The high incidence of reduced antibiotic susceptibility among 
bacteria in ICUs suggests that more effective strategies are needed to 
control the selection and spread of resistant organisms. 
ml Cost-effectiveness of nosocomiai infection 
surveillance methods 
F. Daschner, Uniu. Hospital Freiburg, Environmental Medicine, Freibq, 
Germany 
The costs of various surveillance methods can best be calculated by 
the time required for finding and recording the hospital-acquired 
infections and the costs saved by the positive impact of surveys on 
infection rates. The sensitivity, specificity and the time required for 
data collection of the following surveillance methods will be given: 
laboratory-based ward surveillance, retrospective chart review, pros- 
pective chart review, risk factor analysis, temperature chart review, 
treatment chart review, unit-based staff self-report. 
A simplified surveillance method for nosocomial bloodstream 
infections and a recently tested selective surveillance method for 
device-associated infections in intensive care units will be presented. 
The selective surveillance method required only one-third of the 
time of the surveillance method used in the NNIS ICU surveillance 
protocol. 
Carbapenems in serious infections: 
maximizing the power, minimizing 
resistance 
MYSTIC: targeted surveillance for serious 
infection 
R.G. Masterton. Western General Hospital, Department of Clinical 
Microbiology, Edinbuyh, UK 
Bacterial resistance is increasing worldwide. Carbapenems are 
currently active against most clinically significant organisms, and 
are stable to type 1 (chromosomal) and extended-spectrum beta- 
lactamases. However, resistance to carbapenems, although rare, has 
been described and it is important to monitor this situation con- 
tinuously. The MYSTIC (Meropenem Yearly Susceptibility Test 
Information Collection) survey is an ongoing international sur- 
veillance program designed to assess the in vitro antimicrobial 
activities of meropenem and comparative antibiotics using standard- 
ized NCCLS methodology. On an annual accumulative basis, 
MYSTIC aims to determine patterns of antibiotic resistance within 
defined patient groups, the relationship of resistance to meropenem 
use and the mechanisms of resistance. The results will enable national 
and international comparisons of antibiotic resistance to be made for 
different types of centers. Each year, for at least 3 years, bacterial 
isolates are being obtained from speciallst units (neutropenia, inten- 
sive care, and cystic fibrosis) and from non-specialist centers 
(especially from patients with intra-abdominal and/or lower 
respiratory tract Infections). All centers must be users of meropenem. 
The antibiotic susceptibility (MIC9o values) of isolates for mero- 
penem and comparator antibiotics are determined and the prevalence 
of resistant strains recorded for each antibiotic. In total, nearly 60 
centers will parmipate in the MYSTIC survey worldwide. Interim 
